首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxypheny1)-N-phenylpiperidine-1-carboxamide as novel potent analgesic
【24h】

Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxypheny1)-N-phenylpiperidine-1-carboxamide as novel potent analgesic

机译:发现3 - ((二甲基氨基)甲基)-4-羟基-4-(3-甲氧基苯基1)-N-苯基哌啶-1-甲酰胺作为新型有效镇痛

获取原文
获取原文并翻译 | 示例
           

摘要

Management of moderate to severe pain by clinically used opioid analgesics is associated with a plethora of side effects. Despite many efforts have been dedicated to reduce undesirable side effects, moderate progress has been made. In this work, starting from Tramadol, a series of 3-((dimethylamino)methyl)-4hydroxy-4-(3-methoxyphenyl)piperidine-1-carboxamide derivatives were designed and synthesized, and their in vitro and in vivo activities were evaluated. Our campaign afforded selective opioid receptor (MOR) ligand 2a (K-i (MOR): 7.3 +/- 0.5 nM; K-iDOR: 849.4 +/- 96.6 nM; K-i KOR: 49.1 +/- 6.9 nM) as potent analgesic with ED50 of 3.1 mg/kg in 55 degrees C hot plate model. Its antinociception effect was blocked by opioid antagonist naloxone. High binding affinity toward MOR of compound 2a was associated with water bridge, salt bridge, hydrogen bond and hydrophobic interaction with MOR. The high selectivity of compound 2a for MOR over delta opioid receptor (DOR) and kappa opioid receptor (KOR) was due to steric hindrance of compound 2a with DOR and KOR. 2a, a compound with novel scaffold, could serve as a lead for the development of novel opioid ligands. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:通过临床使用的阿片类药物镇痛药进行中度至严重疼痛的管理与过多的副作用有关。尽管有许多努力致力于减少不期望的副作用,但已经取得了适度的进展。在这项工作中,从曲马多开始,设计并合成了一系列3 - ((二甲基氨基)甲基)-4羟基-4-(3-甲氧基苯基)哌啶-1-甲酰胺衍生物,并评估其体外和体内活性。我们的竞选提供了选择性阿片受体(Mor)配体2a(ki(mor):7.3 +/- 0.5 nm; k-idor:849.4 +/- 96.6 nm; ki Kor:49.1 +/- 6.9 nm)作为ED50的有效镇痛55℃热板模型中为3.1毫克/千克。其抗湿润效应被阿片类药物拮抗剂纳洛酮阻断。对化合物2A的高结合亲和力与水桥,盐桥,氢键和与MOR的疏水相互作用有关。 MOR通过DELTA阿片受体(DOR)和Kappa阿片受体(KAPA OPIOID受体(KAPA)的高选择性是由于具有DOR和KOR的化合物2a的空间阻碍。如图2A所示,一种具有新型支架的化合物,可以用作新型阿片类配体的开发的铅。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号